|
1.
|
Taunton J, Hassig CA and Schreiber SL: A
mammalian histone deacetylase related to the yeast transcriptional
regulator Rpd3p. Science. 272:408–411. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Gurvich N, Tsygankova OM, Meinkoth JL and
Klein PS: Histone deacetylase is a target of valproic acid-mediated
cellular differentiation. Cancer Res. 64:1079–1086. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Gottlicher M, Minucci S, Zhu P, et al:
Valproic acid defines a novel class of HDAC inhibitors inducing
differentiation of transformed cells. EMBO J. 20:6969–6978. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Kuendgen A and Gattermann N: Valproic acid
for the treatment of myeloid malignancies. Cancer. 110:943–954.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Jones J, Juengel E, Mickuckyte A, Hudak L,
Wedel S, Jonas D and Blaheta RA: The histone deacetylase inhibitor
valproic acid alters growth properties of renal cell carcinoma in
vitro and in vivo. J Cell Mol Med. 13:2376–2385. 2009. View Article : Google Scholar
|
|
6.
|
Tan J, Cang S, Ma Y, Petrillo RL and Liu
D: Novel histone deacetylase inhibitors in clinical trials as
anti-cancer agents. J Hematol Oncol. 3:52010. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Lea MA, Ibeh C, Shah N and Moyer MP:
Induction of differentiation of colon cancer cells by combined
inhibition of kinases and histone deacetylase. Anticancer Res.
27:741–748. 2007.PubMed/NCBI
|
|
8.
|
Huang X and Guo B: Adenomatous polyposis
coli determines sensitivity to histone deacetylase
inhibitor-induced apoptosis in colon cancer cells. Cancer Res.
66:9245–9251. 2006. View Article : Google Scholar
|
|
9.
|
Friedmann I, Atmaca A, Chow KU, Jager E
and Weidmann E: Synergistic effects of valproic acid and mitomycin
C in adenocarcinoma cell lines and fresh tumor cells of patients
with colon cancer. J Chemother. 18:415–420. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Biran A, Brownstein M, Haklai R and Kloog
Y: Downregulation of survivin and aurora A by histone deacetylase
and RAS inhibitors: a new drug combination for cancer therapy. Int
J Cancer. 128:691–701. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Koyama M, Izutani Y, Goda AE, et al:
Histone deacetylase inhibitors and
15-deoxy-Delta12,14-prostaglandin J2 synergistically induce
apoptosis. Clin Cancer Res. 16:2320–2332. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Muller S and Kramer OH: Inhibitors of
HDACs – effective drugs against cancer? Curr Cancer Drug Targets.
10:210–228. 2010.
|
|
13.
|
Fedier A, Dedes KJ, Imesch P, von Bueren
AO and Fink D: The histone deacetylase inhibitors suberoylanilide
hydroxamic (Vorinostat) and valproic acid induce irreversible and
MDR1-independent resistance in human colon cancer cells. Int J
Oncol. 31:633–641. 2007.
|
|
14.
|
Weichert W, Roske A, Niesporek S, et al:
Class I histone deacetylase expression has independent prognostic
impact in human colorectal cancer: specific role of class I histone
deacetylases in vitro and in vivo. Clin Cancer Res. 14:1669–1677.
2008. View Article : Google Scholar
|
|
15.
|
Venkataramani V, Rossner C, Iffland L, et
al: Histone deacetylase inhibitor valproic acid inhibits cancer
cell proliferation via down-regulation of the Alzheimer amyloid
precursor protein. J Biol Chem. 285:10678–10689. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Spurling CC, Godman CA, Noonan EJ,
Rasmussen TP, Rosenberg DW and Giardina C: HDAC3 overexpression and
colon cancer cell proliferation and differentiation. Mol Carcinog.
47:137–147. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Chavez-Blanco A, Perez-Plasencia C,
Perez-Cardenas E, et al: Antineoplastic effects of the DNA
methylation inhibitor hydralazine and the histone deacetylase
inhibitor valproic acid in cancer cell lines. Cancer Cell Int.
6:22006. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Satyanarayana A and Kaldis P: Mammalian
cell-cycle regulation: several Cdks, numerous cyclins and diverse
compensatory mechanisms. Oncogene. 28:2925–2939. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Liu N, Fang H, Li Y and Xu W: Recent
research in selective cyclin-dependent kinase 4 inhibitors for
anti-cancer treatment. Curr Med Chem. 16:4869–4888. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Hanashiro K, Kanai M, Geng Y, Sicinski P
and Fukasawa K: Roles of cyclins A and E in induction of centrosome
amplification in p53-compromised cells. Oncogene. 27:5288–5302.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Yamamoto M, Tamakawa S, Yoshie M, Yaginuma
Y and Ogawa K: Neoplastic hepatocyte growth associated with cyclin
D1 redistribution from the cytoplasm to the nucleus in mouse
hepatocarcinogenesis. Mol Carcinog. 45:901–913. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Mejlvang J, Kriajevska M, Vandewalle C, et
al: Direct repression of cyclin D1 by SIP1 attenuates cell cycle
progression in cells undergoing an epithelial mesenchymal
transition. Mol Biol Cell. 18:4615–4624. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Klein EA and Assoian RK: Transcriptional
regulation of the cyclin D1 gene at a glance. J Cell Sci.
121:3853–3857. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Rampalli S, Pavithra L, Bhatt A, Kundu TK
and Chattopadhyay S: Tumor suppressor SMAR1 mediates cyclin D1
repression by recruitment of the SIN3/histone deacetylase 1
complex. Mol Cell Biol. 25:8415–8429. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Sherr CJ and Roberts JM: CDK inhibitors:
positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Weber HO, Samuel T, Rauch P and Funk JO:
Human p14 (ARF)-mediated cell cycle arrest strictly depends on
intact p53 signaling pathways. Oncogene. 21:3207–3212. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Matheu A, Klatt P and Serrano M:
Regulation of the INK4a/ARF locus by histone deacetylase
inhibitors. J Biol Chem. 280:42433–42441. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Hecker RM, Amstutz RA, Wachtel M, Walter
D, Niggli FK and Schafer BW: p21 Downregulation is an important
component of PAX3/FKHR oncogenicity and its reactivation by HDAC
inhibitors enhances combination treatment. Oncogene. 29:3942–3952.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Lee S, Park JR, Seo MS, et al: Histone
deacetylase inhibitors decrease proliferation potential and
multilineage differentiation capability of human mesenchymal stem
cells. Cell Prolif. 42:711–720. 2009. View Article : Google Scholar
|
|
30.
|
Wilson AJ, Byun DS, Nasser S, et al: HDAC4
promotes growth of colon cancer cells via repression of p21. Mol
Biol Cell. 19:4062–4075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Toyoshima H and Hunter T: p27, a novel
inhibitor of G1 cyclin-Cdk protein kinase activity, is related to
p21. Cell. 78:67–74. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Edgar BA and Orr-Weaver TL:
Endoreplication cell cycles: more for less. Cell. 105:297–306.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Freidkin I, Herman M, Tobar A, Chagnac A,
Ori Y, Korzets A and Gafter U: Effects of histone deacetylase
inhibitors on rat mesangial cells. Am J Physiol Renal Physiol.
298:F426–F434. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Ziauddin MF, Yeow WS, Maxhimer JB, et al:
Valproic acid, an antiepileptic drug with histone deacetylase
inhibitory activity, potentiates the cytotoxic effect of
Apo2L/TRAIL on cultured thoracic cancer cells through
mitochondria-dependent caspase activation. Neoplasia. 8:446–457.
2006. View Article : Google Scholar
|
